Étiquette : anandamide

2-Linoleoylglycerol Is a Partial Agonist of the Human Cannabinoid Type 1 Receptor that Can Suppress 2-Arachidonolyglycerol and Anandamide Activity, Leanne Lu et al., 2019

2-Linoleoylglycerol Is a Partial Agonist of the Human Cannabinoid Type 1 Receptor that Can Suppress 2-Arachidonolyglycerol and Anandamide Activity Leanne Lu, Gareth Williams, and Patrick Doherty Cannabis and Cannabinoid Research, 2019, Volume X, Number X Doi : 10.1089/can.2019.0030 Abstract Introduction : The cannabinoid type 1 (CB1) receptor and cannabinoid type 2 (CB2) receptor are widely expressed in the body and anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are their best characterized endogenous ligands. The diacylglycerol lipases (diacylglycerol lipase alpha and diacyl-glycerol lipase beta) not only synthesize essentially all the 2-AG in the body but also generate other monoacylglycerols, including 2-linoleoylglycerol (2-LG). This lipid has been proposed to modulate endocannabinoid [...]

Lire la suite

The endocannabinoid system : an overview, Natalia Battista et al., 2012

The endocannabinoid system : an overview Natalia Battista, Monia Di Tommaso, Monica Bari and Mauro Maccarrone Frontiers in Behavioral Neuroscience, 2012|Volume 6|Article 9 | 1 doi: 10.3389/fnbeh.2012.00009   Upon the identification of anandamide (AEA) in the porcine brain, numerous studies contributed to the current state of knowledge regarding all elements that form the “endocannabinoidsystem (ECS).” How this complex system of receptors, ligands, and enzymes is integrated in helping to regulate fundamental processes at level of central nervous and peripheral systems and how its regulation and dysregulation might counteract disturbances of such functions, is now a days still under investigation. However, the most recent advances on [...]

Lire la suite

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review, Albert Batalla et al., 2019

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review Albert Batalla, Hella Janssen, Shiral S. Gangadin and Matthijs G. Bossong Journal of Clinical Medicine, 2019, 8, 1058 doi : 10.3390/jcm8071058 Abstract : The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the ecacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined [...]

Lire la suite

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats, Marcello Solinas et al., 2006

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats Marcello Solinas, Zuzana Justinova, Steven R. Goldberg and Gianluigi Tanda Journal of Neurochemistry, 2006, 98, 408–419. doi:10.1111/j.1471-4159.2006.03880.x   Abstract Although endogenous cannabinoid systems have been implicated in the modulation of the rewarding effects of abused drugs and food, little is known about the direct effects of endogenous ligands for cannabinoid receptors on brain reward processes. Here we show for the first time that the intravenous administration of anandamide, an endogenous ligand for cannabinoid receptors, and its longer-lasting synthetic analog methanandamide, increase the extracellular dopamine [...]

Lire la suite

Endocannabinoid Signaling and Synaptic Function, Pablo E. Castillo et al., 2012

Endocannabinoid Signaling and Synaptic Function Pablo E. Castillo, Thomas J. Younts, Andres E. Chavez, and Yuki Hashimotodani Neuron, Cell Press, 2012. http://dx.doi.org/10.1016/j.neuron.2012.09.020   Endocannabinoids are key modulators of synaptic function. By activating cannabinoid receptors expressed in the central nervous system, these lipid messengers can regulate several neural functions and behaviors. As experimental tools advance, the repertoire of known endocannabinoid-mediated effects at the synapse, and their underlying mechanism, continues to expand. Retrograde signaling is the principal mode by which endocannabinoids mediate short- and long-term forms of plasticity at both excitatory and inhibitory synapses. However, growing evidence suggests that endocannabinoids can also signal in a nonretrograde manner. [...]

Lire la suite

Cannabinoids in Parkinson’s Disease, Mario Stampanoni Bassi et al., 2017

Cannabinoids in Parkinson's Disease Mario Stampanoni Bassi, Andrea Sancesario, Roberta Morace, Diego Centonze, and Ennio Iezzi Cannabis and Cannabinoid Research, 2017, Volume 2.1 DOI: 10.1089/can.2017.0002 Abstract The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (c-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids [...]

Lire la suite

Familial abnormalities of endocannabinoid signaling in schizophrenia, Dagmar Koethe et al., 2018

Familial abnormalities of endocannabinoid signaling in schizophrenia Dagmar Koethe, Franziska Pahlisch, Martin Hellmich , Cathrin Rohleder , Juliane K. Mueller, Andreas Meyer-Lindenberg , E. Fuller Torrey, Daniele Piomelli and F. Markus Leweke, THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2018 https://doi.org/10.1080/15622975.2018.1449966 ABSTRACT Objectives : Epidemiological and experimental evidence suggests that the endocannabinoid system plays a pathophysiological role in schizophrenia. This is reflected by elevated cerebrospinal levels of the endocannabinoid anandamide in schizophrenia and its initial prodromal states. Methods : We analyzed plasma concentrations of anandamide, 2-arachidonoyl-sn-glycerol, palmitoylethanolamide and oleoylethanolamide from 25 twin pairs discordant for schizophrenia, six discordant for bipolar disorder and eight healthy twin pairs to [...]

Lire la suite

The Endocannabinoid System and its Modulation by Phytocannabinoids, Vincenzo Di Marzo & Fabiana Piscitelli, 2015

The Endocannabinoid System and its Modulation by Phytocannabinoids Vincenzo Di Marzo & Fabiana Piscitelli Neurotherapeutics, 2015, 12, 692–698 DOI 10.1007/s13311-015-0374-6 Abstract : The endocannabinoid system is currently defined as the ensemble of the two 7-transmembrane-domain and G protein-coupled receptors for Δ9-tetrahydrocannabinol (but not for most other plant cannabinoids or phytocannabinoids)—cannabinoid receptor type-1 (CB1R) and cannabinoid receptor type-2 (CB2R); their two most studied endogenous ligands, the “endocannabinoids” N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG); and the enzymes responsible for endocannabinoid metabolism. However, anandamide and 2-AG, and also the phytocannabinoids, have more molecular targets than just CB1R and CB2R. Furthermore, the endocannabinoids, like most other lipid mediators, have more [...]

Lire la suite

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders : a critical overview, G. M. Mandolini et al., 2018

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders : a critical overview G. M. Mandolini, M. Lazzaretti, A. Pigoni, L. Oldani, G. Delvecchio and P. Brambilla Epidemiology and Psychiatric Sciences, 2018, 27, 327–335. © Cambridge University Press 2018 doi : 10.1017/S2045796018000239   Abstract : Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic [...]

Lire la suite

Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity, Matthew B Wall et al.,

Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity Matthew B. Wall, Rebecca Pope, Tom P. Freeman, Oliwia S. Kowalczyk, Lysia Demetriou, Claire Mokrysz, Chandni Hindocha, Will Lawn, Michael A.P. Bloomfield, Abigail M. Freeman, Amanda Feilding, David J. Nutt and H. Valerie Curran Journal of Psychopharmacology,  2019, 1–9 DOI: 10.1177/0269881119841568 journals.sagepub.com/home/jop   Abstract Background : Two major constituents of cannabis are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive component; CBD may buffer the user against the harmful effects of THC. Aims : We examined the effects of two strains of cannabis and placebo on the human brain’s resting-state networks [...]

Lire la suite